AVEO Pharmaceuticals, Inc. (AVEO)
AVEO Price and Sentiment
AVEO Latest news
AVEO Oncology Announces Ficlatuzumab Granted Fast Track Designation by the U.S. FDA for the Treatment of Relapsed or Recurrent Head and Neck Squamous Cell Carcinoma2021-09-20 07:00
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to ficlatuzumab for the treatment of patients with relapsed or recurrent head and neck squamous cell carcinoma (R/R HNSCC). Ficlatuzumab is AVEO's investigational potent humanized immunoglobulin G1 monoclonal antibody that targets hepatocyte growth factor. “The FDA's decisi
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO) today announced that members of its senior management team will participate in two upcoming virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment Conference Date: Monday, September 13 Time: 7:00 a.m. Eastern Time Baird 2021 Global Healthcare Conference Date: Tuesday, September 14 Time: 3:10 p.m. Eastern Time A live webcast of the Baird fireside chat can be accessed by visiting the investors section of the Company's webs
AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q2 2021 Results - Earnings Call Transcript
AVEO (AVEO) delivered earnings and revenue surprises of -2.13% and -2.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) moved lower in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 4.76% year over year to ($0.40), which beat the estimate of ($0.45).
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2021, and provided a business update. “We are pleased to report our first full quarter of FOTIVDA sales, which reflect its commercial uptake since being launched on March 22, 2021. The strength of our early commercial launch reflects the execution of our commercial organization and highlights the high unmet
AVEO Oncology to Announce Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 20212021-07-29 07:00
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will report second quarter 2021 financial results on Thursday, August 05, 2021. AVEO's management team will host a conference call and audio webcast at 4:30 p.m. ET on Thursday, August 5, 2021, to discuss the financial results and provide a business update. The call can be accessed by dialing (844) 882-7841 (U.S. and Canada) or (574) 990-9828 (int
AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
AVEO Oncology to Host Key Opinion Leader Webinar on FOTIVDA® (tivozanib) for Relapsed or Refractory Renal Cell Carcinoma2021-07-08 16:05
BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial and clinical development stage biopharmaceutical company, today announced that it will host a key opinion leader (KOL) webinar focusing on FOTIVDA® (tivozanib), AVEO's oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies, on Frid
AVEO Oncology has had a transformational 2021 thus far. The company's flagship product, FOTIVDA, has finally been approved in advanced RCC and was subsequently launched into a relatively unclaimed market. The company reported their Q1 earnings that revealed that FOTIVDA is already gaining some traction. However, AVEO will have to work hard to get payers, providers, and patients to commit.